A. Réanimation-médicale and P. Publique-hôpitaux-de, Hôpital Saint-Antoine, 184 rue du Faubourg Saint Antoine

L. Rue-de and . École-de-médecine, 8 Réanimation Polyvalente, Centre Hospitalier de Metz, 1 Place Philippe de Vigneulles, pp.6-8

M. Fiacre, R. Dellinger, S. Townsend, W. Linde-zwirble, J. Marshall et al., 12 Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum, Hoppe-Seyler-Straße 3, Tübingen, 72076, Germany. 13 Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin der Westf, Wilhelms- Universität, Albert-Schweitzer-Str The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis, 11 Réanimation et Maladies Infectieuses, pp.222-231, 2010.

E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin et al., Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock, New England Journal of Medicine, vol.345, issue.19, pp.1368-1377, 2001.
DOI : 10.1056/NEJMoa010307

R. Dellinger, M. Levy, J. Carlet, J. Bion, M. Parker et al., Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008, Critical Care Medicine, vol.36, issue.1, pp.296-327, 2008.
DOI : 10.1097/01.CCM.0000298158.12101.41

F. Schortgen, E. Girou, N. Deye, L. Brochard, . Cryco-study et al., The risk associated with hyperoncotic colloids in patients with shock, Intensive Care Medicine, vol.363, issue.Suppl 17, pp.2157-2168, 2008.
DOI : 10.1007/s00134-008-1225-2

F. Schortgen, J. Lacherade, F. Bruneel, I. Cattaneo, F. Hemery et al., Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study, The Lancet, vol.357, issue.9260, pp.911-916, 2001.
DOI : 10.1016/S0140-6736(00)04211-2

F. Brunkhorst, C. Engel, F. Bloos, A. Meier-hellmann, M. Ragaller et al., Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis, New England Journal of Medicine, vol.358, issue.2, pp.125-139, 2008.
DOI : 10.1056/NEJMoa070716

C. Jungheinrich and T. Neff, Pharmacokinetics of Hydroxyethyl Starch, Clinical Pharmacokinetics, vol.92, issue.7, pp.681-699, 2005.
DOI : 10.2165/00003088-200544070-00002

M. Westphal, M. James, S. Kozek-langenecker, R. Stocker, B. Guidet et al., Hydroxyethyl Starches, Anesthesiology, vol.111, issue.1, pp.187-202, 2009.
DOI : 10.1097/ALN.0b013e3181a7ec82

C. Vs, Hydroxyethyl Starch Trial (CHEST) Management Committee: The Crystalloid vs Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality, Intensive Care Med, vol.37, pp.816-823, 2011.

R. Bellomo, C. Ronco, J. Kellum, R. Mehta, and P. Palevsky, Acute renal failure definition , outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Critical Care, vol.8, issue.4, pp.204-212, 2004.
DOI : 10.1186/cc2872

S. Bagshaw, C. George, and R. Bellomo, A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients, Nephrology Dialysis Transplantation, vol.23, issue.5, pp.1569-1574, 2008.
DOI : 10.1093/ndt/gfn009

J. Mishra, C. Dent, R. Tarabishi, M. Mitsnefes, Q. Ma et al., Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery, The Lancet, vol.365, issue.9466, pp.1231-1238, 2005.
DOI : 10.1016/S0140-6736(05)74811-X

J. Waitzinger, F. Bepperling, G. Pabst, J. Opitz, A. Fackelmayer et al., Effect of a New Hydroxyethyl Starch (HES) Specification [6% HES (130/0.4)] on Blood and Plasma Volumes after Bleeding in 12 Healthy Male Volunteers, Clinical Drug Investigation, vol.17, issue.2, pp.119-125, 1999.
DOI : 10.2165/00044011-199917020-00006

M. Cittanova, I. Leblanc, C. Legendre, C. Mouquet, B. Riou et al., Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients, The Lancet, vol.348, issue.9042, pp.1620-1622, 1996.
DOI : 10.1016/S0140-6736(96)07588-5

V. Blasco, M. Leone, F. Antonini, A. Geissler, J. Albanèse et al., Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation, British Journal of Anaesthesia, vol.100, issue.4, pp.504-548, 2008.
DOI : 10.1093/bja/aen001

F. Hokema, S. Ziganshyna, M. Bartels, U. Pietsch, T. Busch et al., Is perioperative low molecular weight hydroxyethyl starch infusion a risk factor for delayed graft function in renal transplant recipients?, Nephrology Dialysis Transplantation, vol.26, issue.10, pp.3373-3378, 2011.
DOI : 10.1093/ndt/gfr017

. Guidet, Critical Care, p.94, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01265885

L. Muller, S. Jaber, N. Molinari, L. Favier, J. Larché et al., Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock, Critical Care, vol.16, issue.1, p.34, 2012.
DOI : 10.1097/01.CCM.0000194725.48928.3A
URL : https://hal.archives-ouvertes.fr/hal-01137076

X. Du, W. Hu, Q. Xia, Z. Huang, G. Chen et al., Hydroxyethyl Starch Resuscitation Reduces the Risk of Intra-Abdominal Hypertension in Severe Acute Pancreatitis, Pancreas, vol.40, issue.8, pp.1220-1225, 2011.
DOI : 10.1097/MPA.0b013e3182217f17

N. Boussekey, R. Darmon, J. Langlois, S. Alfandari, P. Devos et al., Resuscitation with low volume hydroxyethylstarch 130kDa/0.4 is not associated with acute kidney injury, Critical Care, vol.14, issue.2, p.40, 2010.
DOI : 10.1186/cc8920

G. Godet, J. Lehot, G. Janvier, A. Steib, D. Castro et al., Safety of HES 130/0.4 (Voluven??) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery, European Journal of Anaesthesiology, vol.25, issue.12, pp.986-994, 2008.
DOI : 10.1017/S026502150800447X

T. Neff, M. Doelberg, C. Jungheinrich, A. Sauerland, D. Spahn et al., Repetitive Large-Dose Infusion of the Novel Hydroxyethyl Starch 130/0.4 in Patients with Severe Head Injury, Anesthesia & Analgesia, vol.96, pp.1453-1459, 2003.
DOI : 10.1213/01.ANE.0000061582.09963.FD

P. Van-der-linden, D. Hert, S. Deraedt, D. Cromheecke, S. et al., Hydroxyethyl Starch 130/0.4 Versus Modified Fluid Gelatin for Volume Expansion in Cardiac Surgery Patients: The Effects on Perioperative Bleeding and Transfusion Needs, Anesthesia & Analgesia, vol.101, issue.3, pp.629-634, 2005.
DOI : 10.1213/01.ANE.0000175216.53374.27

M. James, W. Michell, I. Joubert, A. Nicol, P. Navsaria et al., Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma), British Journal of Anaesthesia, vol.107, issue.5, pp.693-702, 2011.
DOI : 10.1093/bja/aer229

C. Jungheinrich, R. Scharpf, M. Wargenau, F. Bepperling, and J. Baron, The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 ml) in mild-to-severe renal impairment, Anesth Analg, vol.95, pp.544-551, 2002.

B. Ellger, J. Freyhoff, H. Van-aken, M. Booke, and M. Marcus, High-dose volume replacement using HES 130/0.4 during major surgery: Impact on coagulation and incidence of postoperative itching, pp.63-68, 2006.

S. Kozek-langenecker, C. Jungheinrich, W. Sauermann, and P. Van-der-linden, The Effects of Hydroxyethyl Starch 130/0.4 (6%) on Blood Loss and Use of Blood Products in Major Surgery: A Pooled Analysis of Randomized Clinical Trials, Anesthesia & Analgesia, vol.107, issue.2, pp.382-390, 2008.
DOI : 10.1213/ane.0b013e31817e6eac

J. Leuschner, J. Opitz, A. Winkler, R. Scharpf, and F. Bepperling, Tissue Storage of 14 C-Labelled Hydroxyethyl Starch (HES) 130/0.4 and HES 200/0.5 after Repeated Intravenous Administration to Rats, Drugs in R & D, vol.14, issue.6, pp.331-338, 2003.
DOI : 10.2165/00126839-200304060-00001

D. Metze, S. Reimann, Z. Szepfalusi, B. Bohle, D. Kraft et al., Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves, British Journal of Dermatology, vol.83, issue.4, pp.553-559, 1997.
DOI : 10.1111/j.1365-2133.1994.tb08529.x

F. Michard and J. Teboul, Predicting Fluid Responsiveness in ICU Patients, Chest, vol.121, issue.6, pp.2000-2008, 2002.
DOI : 10.1378/chest.121.6.2000

S. Finfer, S. Mcevoy, R. Bellomo, C. Mcarthur, J. Myburgh et al., Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis, Intensive Care Med, vol.37, pp.86-96, 2011.

A. Perner, N. Haase, J. Wetterslev, A. Aneman, J. Tenhunen et al., Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): Study protocol, design and rationale for a double-blinded, randomised clinical trial, Trials, vol.270, issue.1, p.24, 2011.
DOI : 10.1001/jama.1993.03510240069035

. Guidet, Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study, Critical Care, vol.16, issue.3, p.94, 2012.
DOI : 10.1186/1745-6215-12-24
URL : https://hal.archives-ouvertes.fr/inserm-00706029